Trial Profile
Antiplatelet Effects of Evolocumab in Patients With Peripheral Arterial Disease
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 21 Feb 2024
Price :
$35
*
At a glance
- Drugs Evolocumab (Primary) ; HMG-CoA reductase inhibitors
- Indications Peripheral arterial disorders
- Focus Pharmacodynamics
- 26 Jun 2023 Status changed from recruiting to discontinued (Research group transferred to another hospital).
- 21 Aug 2018 Planned End Date changed from 1 Jul 2018 to 1 Jul 2019.
- 21 Aug 2018 Planned primary completion date changed from 1 May 2018 to 1 May 2019.